2693MO COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS)

A. Dufresne; M. Brahmi; Claire Cropet; R. Bahleda; Sarah Watson; P. Pautier; I.L. Ray-Coquard; Isabelle Aerts; Axel Le Cesne; Anne Sophie Defachelles; F. Duffaud; G. Garin; M. Bernardin; Cécile Guichard; Laurie Tonon; Cyril Dégletagne; Bertrand Dubois; David Pérol; Jean Yves Blay; N. Corradini

doi:10.1016/j.annonc.2025.08.3304

Article2004

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

Dimitrios Bafaloukos, C. Papadimitriou, Helena Linardou, Gerasimos Aravantinos, Pavlos Papakostas, D. Skarlos, P. Kosmidis, George Fountzilas, Helen Gogas, Haralabos P. Kalofonos, Meletios A Dimopoulos

Preprint2023

Data from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, Camille Chakiba, Alban Bessede, Michèle Kind, Émilie Toulza, Marina Pulido, Sabrina Albert, Jean-Philippe Guégan, Sophie Cousin, Simone Mathoulin‐Pélissier, Raul Perret, Sabrina Croce, Jean Yves Blay, Isabelle Ray‐Coquard, Anne Floquet, Antoîne Italiano

Preprint2023

Data from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, Camille Chakiba, Alban Bessede, Michèle Kind, Émilie Toulza, Marina Pulido, Sabrina Albert, Jean-Philippe Guégan, Sophie Cousin, Simone Mathoulin‐Pélissier, Raul Perret, Sabrina Croce, Jean Yves Blay, Isabelle Ray‐Coquard, Anne Floquet, Antoîne Italiano

Article2022

1527TiP CONGRATS-combination of nivolumab plus relatlimab in patients with advanced or metastatic soft-tissue sarcoma: A proof-of-concept randomized phase II study

Mariella Spalato Ceruso, S. Albert, A. Italiano, M. Toulmonde, S. Cousin, T. Grellety, Jean Yves Blay, B. Verret, C. Auzanneau, V. Valade, L. Poignie, B. Lortal, M. Kind, F. Le Loarer, M. Pulido

Preprint2023

Supplementary Figure from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, Camille Chakiba, Alban Bessede, Michèle Kind, Émilie Toulza, Marina Pulido, Sabrina Albert, Jean-Philippe Guégan, Sophie Cousin, Simone Mathoulin‐Pélissier, Raul Perret, Sabrina Croce, Jean Yves Blay, Isabelle Ray‐Coquard, Anne Floquet, Antoîne Italiano

2693MO COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS)

Discussion(0)

Related publications

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

Data from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Data from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

1527TiP CONGRATS-combination of nivolumab plus relatlimab in patients with advanced or metastatic soft-tissue sarcoma: A proof-of-concept randomized phase II study

Supplementary Figure from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study